Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
Public ClinicalTrials.gov record NCT00004255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Randomized phase II/III trial to compare the effectiveness of treated bone marrow with that of untreated bone marrow in preventing graft-versus-host disease in patients with acute or chronic leukemia who are undergoing bone marrow transplantation.
Study identification
- NCT ID
- NCT00004255
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- Not listed
Conditions and interventions
Interventions
- anti-thymocyte globulin Biological
- filgrastim Biological
- cyclophosphamide Drug
- fludarabine phosphate Drug
- methylprednisolone Drug
- tacrolimus Drug
- allogeneic bone marrow transplantation Procedure
- in vitro-treated bone marrow transplantation Procedure
- radiation therapy Radiation
Biological · Drug · Procedure + 1 more
Eligibility (public fields only)
- Age range
- 12 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2000
- Primary completion
- Not listed
- Completion
- Apr 30, 2003
- Last update posted
- Jul 9, 2013
2000 – 2003
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego Cancer Center | La Jolla | California | 92093-0658 | — |
| Presbyterian-St Luke's Medical Center | Denver | Colorado | 80218 | — |
| Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Shands Hospital and Clinics, University of Florida | Gainesville | Florida | 32610-100277 | — |
| Indiana Blood and Marrow Transplantation | Indianapolis | Indiana | 46202 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201-1379 | — |
| University of Rochester Cancer Center | Rochester | New York | 14642 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73190 | — |
| Oregon Cancer Center | Portland | Oregon | 97201-3098 | — |
| Hahnemann University Hospital | Philadelphia | Pennsylvania | 19102-1192 | — |
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| South Texas Cancer Institute | San Antonio | Texas | 78229 | — |
| Massey Cancer Center | Richmond | Virginia | 23298-0037 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00004255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2013 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00004255 live on ClinicalTrials.gov.